NCT05406440View on ClinicalTrials.gov

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Schizophrenia
Interventions
DRUG

MK-8189

MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.

DRUG

Placebo

MK-8189 dose-matching placebo tablets will be administered orally QD.

Trial Locations (3)

91206

California Clinical Trials Medical Group managed by PAREXEL ( Site 0002), Glendale

92845

Collaborative Neuroscience Research, LLC ( Site 0004), Garden Grove

08053

Hassman Research Institute Marlton Site ( Site 0003), Marlton

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY